Your Navigation:PCAR > Abstract
Search pcar
Pharmaceutical Care and Research: 2018; 18(4):241-246
DOI: 10.5428/pcar20180401
Advances in animal model,pathogenesis and anti-fibrosis treatment of pulmonary fibrosis induced by paraquat
1. LI Sha(Department of Pharmacy,People’s Hospital of Hunan Province,Changsha 410005,China
2. LIU Wen(Department of Pharmacy,People’s Hospital of Hunan Province,Changsha 410005,China
ABSTRACT  Pulmonary fibrosis induced by paraquat is an important factor leading to death of patients, and is also a hot and difficult research topic both at home and abroad. Various studies have shown that the onset time for typical pulmonary fibrosis in the paraquat animal model is approximately 14 to 28 days. However, latest studies have not yet fully elucidated the intoxication mechanism involved. Research findings are mostly focused on the active uptake and accumulation features of paraquat. Furthermore, paraquat itself is an electron receptor that acts on intracellular oxidation reduction reaction and produces large numbers of active free radicals, resulting in disorder of cytokine network, imbalance of protease and dysfunction of mitochondria and accelerating the occurrence and development of fibrosis. At present, the research on anti-fibrosis treatment is mainly focused on herbal medicine, which is now still at the experimental stage and clinical data in this respect remain insufficient. Therefore, this paper gives a comprehensive review on the latest animal model, pathogenesis and treatment of pulmonary fibrosis induced by paraquat, so that solid evidence could be provided for the research and treatment of paraquat toxication.
Welcome to PCAR! You are the number 452 reader of this article!
Please cite this article as:
LI Sha,LIU Wen,. Advances in animal model,pathogenesis and anti-fibrosis treatment of pulmonary fibrosis induced by paraquat[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2018; 18(4): 241-246.
1. HONG GuangLiang, CAI QiQi, TAN JiaPing, et al. Mifepristone-inducible recombinant adenovirus attenuates paraquat-induced lung injury in rats[J]. Hum Exp Toxicol, 2015, 34(1):32-43.
2. LIU TianJu, De Los Santos F G, Phan S H. The bleomycin model of pulmonary fibrosis[J]. Methods Mol Biol, 2017, 1627:27-42.
3. JIANG YinSong, MA YuYing, WANG ZhanQing, et al. Therapeutic effects of smecta or smectite powder on rats with paraquat toxication[J]. World J Emerg Med, 2013, 4(2):144-150.
4. XU YiHeng, TAI WenLin, QU XiaoYuan, et al. Rapamycin protects against paraquat-induced pulmonary fibrosis: activation of Nrf2 signaling pathway[J]. Biochem Biophys Res Commun, 2017, 490(2):535540.
5. XU XiaoLi, WANG Wei, SONG ZuJun, et al. Imaging in detecting sites of pulmonary fibrosis induced by paraquat[J]. World J Emerg Med, 2011, 2(1):45-49.
6. Malekinejad H, Mehrabi M, Khoramjouy M,et al. Antifibrotic effect of atorvastatin on paraquat-induced pulmonary fibrosis: role of PPARγ receptors[J]. Eur J Pharmacol, 2013, 720(1-3):294-302.
7. Tomita M, Okuyama T, Katsuyama H, et al. Mouse model of paraquat-poisoned lungs and its gene expression profile[J]. Toxicology, 2007, 231(2-3):200-209.
8. Dinis-Oliveira R J, Duarte J A, Sánchez-Navarro A, et al. Paraquat poisoning: mechanisms of lung toxicity, clinical features, and treatment[J]. Crit Rev Toxicol, 2008, 38(1):13-71.
9. SUN Bin, CHEN YuGuo. Advances in the mechanism of paraquat-induced pulmonary injury[J]. Eur Rev Med Pharmacol Sci, 2016, 20(8):1597-1602.
10. LIU ShuLin, LIU Kan, SUN Qiang, et al. Consumption of hydrogen water reduces paraquat-induced acute lung injury in rats[J]. J Biomed Biotechnol, 2011:305086. doi: 10.1155/2011/305086.
11. Knudsen L, Ruppert C, Ochs M. Tissue remodelling in pulmonary fibrosis[J]. Cell Tissue Res, 2017, 367(3):607-626.
12. Mezzano V, Cabrera D, Vial C, et al. Constitutively activated dystrophic muscle fibroblasts show a paradoxical response to TGF-β and CTGF/CCN2[J]. J Cell Commun Signal, 2007, 1(3-4):205-217.
13. ZHAO Feng, SHI DanYang, LI TieGang, et al. Silymarin attenuates paraquat-induced lung injury via Nrf2-mediated pathway in vivo and in vitro[J]. Clin Exp Pharmacol Physiol, 2015, 42:988-998.
14. Amirshahrokhi K, Khalili A R. Carvedilol attenuates paraquat-induced lung injury by inhibition of proinflammatory cytokines, chemokine MCP-1, NF-κB activation and oxidative stress mediators[J]. Cytokine, 2016, 88:144-153.
15. CHEN Tong, WANG RuoNing, JIANG WenJiang, et al. Protective effect of astragaloside Ⅳ against paraquat-induced lung injury in mice by suppressing rho signaling[J]. Inflammation, 2016, 39(1):483-492.
16. Amirshahrokhi K. Anti-inflammatory effect of thalidomide in paraquat-induced pulmonary injury in mice[J]. Int Immunopharmacol, 2013, 17(2):210-215.
17. Rasooli R, Pourgholamhosein F, Kamali Y, et al. Combination therapy with pirfenidone plus prednisolone ameliorates paraquat-induced pulmonary fibrosis[J]. Inflammation, 2018,41(1):134-142.
18. Wójcik-Pszczola K, Jakiela B, Plutecka H, et al. Connective tissue growth factor regulates transition of primary bronchial fibroblasts to myofibroblasts in asthmatic subjects[J]. Cytokine, 2018,102:187-190.
19. Mishra D K, Srivastava P, Sharma A, et al. Translationally controlled tumor protein (TCTP) is required for TGF-β1 induced epithelial to mesenchymal transition and influences cytoskeletal reorganization[J]. Biochim Biophys Acta,2018,1865(1):67-75.
20. Fujimoto H, D’Alessandro-Gabazza C N, Palanki M S S, et al. Inhibition of nuclear factor-κB in T cells suppresses lung fibrosis[J].Am J Respir Crit Care Med,2007, 176:1251-1260.
21. SUN Xia, CHEN ErJun, DONG Rui, et al. Nuclear factor (NF)-κB p65 regulates differentiation of human and mouse lung fibroblasts mediated by TGF-β[J]. Life Sci, 2015, 122:8-14.
22. Ishibuchi H, Abe M, Yokoyama Y, et al. Induction of matrix metalloproteinase-1 by small interfering RNA targeting connective tissue growth factor in dermal fibroblasts from patients with systemic sclerosis[J]. Exp Dermatol, 2010, 19(8):e111-e116.
23. HUANG Min, YANG HuiFang, ZHU LingQin,et al. Inhibition of connective tissue growth factor attenuates paraquat-induced lung fibrosis in a human MRC-5 cell line[J]. Environ Toxicol, 2016, 31(11):1620-1626.
24. Rasooli R, Rajaian H, Pardakhty A, et al. Preference of aerosolized pirfenidone to oral intake: an experimental model of pulmonary fibrosis by paraquat[J]. J Aerosol Med Pulm Drug Deliv, 2018,31(1):25-32.
25. Rajasekaran S, Vaz M, Reddy S P. Fra-1/AP-1 transcription factor negatively regulates pulmonary fibrosis in vivo[J]. Plos One, 2012, 7(7):e41611.
26. WANG BoLiang, TU YanYang, FU JianFang, et al. Unbalanced MMP/TIMP-1 expression during the development of experimental pulmonary fibrosis with acute paraquat poisoning[J]. Mol Med Rep, 2011, 4(2):243-248.
27. CHEN Yan, NIE YiChu, LUO YuLong, et al. Protective effects of naringin against paraquat-induced acute lung injury and pulmonary fibrosis in mice[J]. Food Chem Toxicol,2013, 58:133-140.
28. Sanders L H, Paul K C, Howlett E H, et al. Base excision repair variants and pesticide exposure increase Parkinson’s disease risk[J]. Toxicol Sci, 2017, 158(1):188-198.
29. Li L R, Sydenham E, Chaudhary B. et al. Glucocorticoid with cyclophosphamide for paraquat-induced lung fibrosis(review)[J].Cochrane Database Syst Rev,2012,(7):CD008084.
30. Wollin L, Maillet I, Quesniaux V,et al. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis[J]. J Pharmacol Exp Ther, 2014, 349(2):209-220.
31. Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis[J]. N Engl J Med, 2011, 365(12):1079-1087.
32. Dimitroulis I A. Nintedanib: a novel therapeutic approach for idiopathic pulmonary fibrosis[J]. Respir Care, 2014, 59(9):1450-1455.
33. GONG Ping, LU ZhiDan, XING Jing, et al. Traditional Chinese medicine Xuebijing treatment is associated with decreased mortality risk of patients with moderate paraquat poisoning[J]. Plos One, 2015, 10(4):e0123504.
34. SHI XiaoFeng, ZHANG Yue, WANG YongQiang. Impact of Xuebijing and ulinastatin as assistance for hemoperfusion in treating acute paraquat poisoning[J]. Int J Clin Exp Med, 2015, 8(8):14018-14023.
35. LIU MingWei, SU MeiXian, ZHANG Wei, et al. Protective effect of Xuebijing injection on paraquat-induced pulmonary injury via down-regulating the expression of p38 MAPK in rats[J]. BMC Complement Altern Med, 2014, 14(1):498.
36. Tyagi N, Dash D, Singh R. Curcumin inhibits paraquat induced lung inflammation and fibrosis by extracellular matrix modifications in mouse model[J]. Inflammopharmacology, 2016, 24(6):335-345.
37. Punithavathi D, Venkatesan N, Babu M. Protective effects of curcumin against amiodarone-induced pulmonary fibrosis in rats[J]. Br J Pharmacol, 2003, 139(7):1342-1350.
38. Mohammadi-Karakani A, Ghazi-Khansari M, Sotoudeh M. Lisinopril ameliorates paraquat-induced lung fibrosis[J]. Clin Chim Acta, 2006, 367(1-2):170-174.
39. HUANG Yang, YIN Wen, JIA Bin,et al. Protection of bone marrow mesenchymal stem cells from acute lung injury induced by paraquat poisoning[J]. Clin Toxicol, 2011, 49(4):298-302
《药学服务与研究》杂志社 All Rights Reserved 网站备案号:鲁B2-20061008
·地址:上海市杨浦区长海路168号18号楼东三楼 邮政编码:200433
·联系电话(传真):86-21-65519829, 021-31162330